Clinical trial design during and beyond the pandemic: the I-SPY COVID trial

The I-SPY COVID Consortium

doi:10.1038/s41591-021-01617-x

Clinical trial design during and beyond the pandemic: the I-SPY COVID trial

The I-SPY COVID Consortium

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	9-11
Number of pages	3
Journal	Nature Medicine
Volume	28
Issue number	1
DOIs	https://doi.org/10.1038/s41591-021-01617-x
State	Published - Jan 2022

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/s41591-021-01617-x

Cite this

@article{44cc9ec5341d4baf88c8796014a5c26d,

title = "Clinical trial design during and beyond the pandemic: the I-SPY COVID trial",

author = "{The I-SPY COVID Consortium} and Calfee, {Carolyn S.} and Liu, {Kathleen D.} and Beitler, {Jeremy R.} and Asare, {Adam L.} and Berger, {Paul A.} and Coleman, {Melissa H.} and Alessio Crippa and Andrea Discacciati and Martin Eklund and Files, {Daniel C.} and Sheetal Gandotra and Gibbs, {Kevin W.} and Paul Henderson and Levitt, {Joseph E.} and Ruixiao Lu and Matthay, {Michael A.} and Meyer, {Nuala J.} and Russell, {Derek W.} and Thomas, {Karl W.} and Esserman, {Laura J.} and Mittel, {Aaron M.} and Dzierba, {Amy L.} and Purnema Madahar and Serra, {Alexis L.} and Amanda Rosen and Ivan Garcia and Justin Muir and John Schicchi and Anita Darmanian and Romina Wahab and Katarzyna Gosek and Auld, {Sara C.} and Adelman, {Max W.} and Nugent, {Katherine L.} and Harris, {Gavin H.} and Christina Creel-Bulos and Philip Yang and Detelich, {Joshua F.} and Christine Spainhour and Cobb, {Nathan K.} and Rajiv Sonti and Orr, {Lindsey A.} and Robinson, {Philip A.} and Farjad Sarafian and Esmeralda Martinez and Patrice Jones and Julie Nguyen and Obermiller, {Timothy F.} and Bethany Weiler-Lisowski and Lucia Kufa",

note = "Funding Information: L.E. is an unpaid member of the board of directors of Quantum Leap Healthcare Collaborative (QLHC, the study sponsor), and received grant funding from QLHC for the I-SPY TRIAL. L.E. is a member of the Blue Cross/Blue Shield Medical Advisory Panel and receives reimbursement for time and travel. L.E. has a grant from Merck for an Investigator-initiated trial of ductal carcinoma in situ. C.C. received funding for this article from QHLC, as well as other funding from the NIH and Roche/Genentech. C.C. also provides consulting services for Quark, Vasomune and Gen1e Life Sciences. K.D.L. is a stockholder of Amgen Inc. A.D..B is a member of the Scientific Advisory Board Committee of Caris Life Sciences. All other authors report no competing interests.",

year = "2022",

month = jan,

doi = "10.1038/s41591-021-01617-x",

language = "English (US)",

volume = "28",

pages = "9--11",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Clinical trial design during and beyond the pandemic

T2 - the I-SPY COVID trial

AU - The I-SPY COVID Consortium

AU - Calfee, Carolyn S.

AU - Liu, Kathleen D.

AU - Beitler, Jeremy R.

AU - Asare, Adam L.

AU - Berger, Paul A.

AU - Coleman, Melissa H.

AU - Crippa, Alessio

AU - Discacciati, Andrea

AU - Eklund, Martin

AU - Files, Daniel C.

AU - Gandotra, Sheetal

AU - Gibbs, Kevin W.

AU - Henderson, Paul

AU - Levitt, Joseph E.

AU - Lu, Ruixiao

AU - Matthay, Michael A.

AU - Meyer, Nuala J.

AU - Russell, Derek W.

AU - Thomas, Karl W.

AU - Esserman, Laura J.

AU - Mittel, Aaron M.

AU - Dzierba, Amy L.

AU - Madahar, Purnema

AU - Serra, Alexis L.

AU - Rosen, Amanda

AU - Garcia, Ivan

AU - Muir, Justin

AU - Schicchi, John

AU - Darmanian, Anita

AU - Wahab, Romina

AU - Gosek, Katarzyna

AU - Auld, Sara C.

AU - Adelman, Max W.

AU - Nugent, Katherine L.

AU - Harris, Gavin H.

AU - Creel-Bulos, Christina

AU - Yang, Philip

AU - Detelich, Joshua F.

AU - Spainhour, Christine

AU - Cobb, Nathan K.

AU - Sonti, Rajiv

AU - Orr, Lindsey A.

AU - Robinson, Philip A.

AU - Sarafian, Farjad

AU - Martinez, Esmeralda

AU - Jones, Patrice

AU - Nguyen, Julie

AU - Obermiller, Timothy F.

AU - Weiler-Lisowski, Bethany

AU - Kufa, Lucia

N1 - Funding Information: L.E. is an unpaid member of the board of directors of Quantum Leap Healthcare Collaborative (QLHC, the study sponsor), and received grant funding from QLHC for the I-SPY TRIAL. L.E. is a member of the Blue Cross/Blue Shield Medical Advisory Panel and receives reimbursement for time and travel. L.E. has a grant from Merck for an Investigator-initiated trial of ductal carcinoma in situ. C.C. received funding for this article from QHLC, as well as other funding from the NIH and Roche/Genentech. C.C. also provides consulting services for Quark, Vasomune and Gen1e Life Sciences. K.D.L. is a stockholder of Amgen Inc. A.D..B is a member of the Scientific Advisory Board Committee of Caris Life Sciences. All other authors report no competing interests.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85123901438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123901438&partnerID=8YFLogxK

U2 - 10.1038/s41591-021-01617-x

DO - 10.1038/s41591-021-01617-x

M3 - Letter

C2 - 35058620

AN - SCOPUS:85123901438

SN - 1078-8956

VL - 28

SP - 9

EP - 11

JO - Nature Medicine

JF - Nature Medicine

IS - 1

ER -

Clinical trial design during and beyond the pandemic: the I-SPY COVID trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this